Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up

International Journal of Rheumatic Diseases

Volumn 15, Issue 3, 2012, Pages 330-335

  Dewedar, Ahmed M ^a   Shalaby, Medhat A ^b,c   Al Homaid, Sulaiman ^b   Mahfouz, Ahmed M ^c   Shams, Osama A ^a   Fathy, Ahmed ^c  

^a MINISTRY OF HEALTH   (Saudi Arabia)

^b AL AZHAR UNIVERSITY   (Egypt)

^c KING KHALID UNIVERSITY   (Saudi Arabia)

Author keywords

Adverse effects; Anti TNF ; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABORTION; ADULT; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SAUDI ARABIA; SOLID TUMOR; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; RISK FACTORS; SAUDI ARABIA; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84862533610     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2012.01715.x     Document Type: Article

References (34)

1. Ozer HTE, Ozbalkan Z (2010) Clinical efficacy of TNF-α inhibitors: an update. Int J Clin Rheumatol 5, 101-15.
2. Moreland LW, Heck LW Jr, Koopman WJ (1997) Biologic agents for treating rheumatoid arthritis. Arthritis Rheum 40, 397-409.
3. Antoni C, Braun J (2002) Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 20 (Suppl 28), S152-7.
4. Smolen JS (2010) How well can we compare different biologic agents for RA? Nat Rev Rheumatol 6, 247-8.
5. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-85.
6. Gartlehner G (2006) The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systemic review and meta-analysis. J Rheumatol 33, 2398-408.
7. Chang J, Girgis L (2007) Clinical use of anti TNF-α biological agents. A guide for GPs. Aust Fam Physician 36, 1035-8.
8. De Keyser F (2011) Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev 7, 77-87.
9. Alves-Rosa MF, Palermo MS, Isturiz MA (1998) Enhancement of immune complex clearance by TNF-alpha in a murine model. Clin Immunol Immunopathol 89, 214-21.
10. Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68, 1136-45.
11. Galloway JB, Hyrich KL, Mercer LK, et al. (2010) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 51, 124-31.
12. Carmona L, Hernandez-Garcia C, Vadillo C, et al. (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30, 1436-9.
13. Allali F, Rkain H, Faik A, El HS, Hajjaj-Hassouni N (2005) Prevalence and clinical characteristics of tuberculosis in rheumatoid arthritis patients. Clin Rheumatol 24, 656-7.
14. Yoshinaga Y, Kanamori T, Ota Y, et al. (2004) Clinical characteristics of Mycobacterium tuberculosis infection among rheumatoid arthritis patients. Mod Rheumatol 14, 143-8.
15. Yamada T, Nakajima A, Inoue E, et al. (2006) Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65, 1661-3.
16. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE (2005) The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34, 819-36.
17. ®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65, 889-94.
18. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; BSRBR Control Centre Consortium, Symmons DPM; on behalf of the BSR Biologics Register (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69, 522-8.
19. Askling J, Fored CM, Brandt L, et al. (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52, 1986-92.
20. Brassard P, Kezouh A, Suissa S (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43, 717-22.
21. Tubach F, Salmon D, Ravaud P, et al. (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60, 1884-94.
22. Gomez-Reino JJ, Carmona L, Angel DM (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57, 756-61.
23. Denis B, Lefort A, Flipo RM, et al. (2008) Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 14, 183-6.
24. Strangfeld A, Listing J, Herzer P, et al. (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301, 737-44.
25. Wendling D, Streit G, Toussirot E, Prati C (2008) Herpes zoster in patients taking TNF-alpha antagonists for chronic inflammatory joint disease. Joint Bone Spine 75, 540-3.
26. McDonald JR, Zeringue AL, Caplan L, et al. (2009) Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 48, 1364-71.
27. Smitten AL, Choi HK, Hochberg MC, et al. (2007) The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57, 1431-8.
28. Furst DE (2010) The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 39, 327-46.
29. Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68, 25-32.
30. Singh JA, Christensen R, Wells GA, et al. (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev (4), Art. No.: CD007848.
31. Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68, 1136-45.
32. Bongartz T, Warren FC, Mines D, et al. (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68, 1177-83.
33. Monika Østensen M, Förger F (2011) Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol 23, 293-8.
34. Ben-Horin S, Yavzori M, Katz L, et al. (2010) Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 8, 475-6.